UK News

European regulator greenlights AstraZeneca coronavirus vaccine after reports of blood clots


A dose of the Oxford/AstraZeneca coronavirus vaccine is prepared by a member of the Hampshire Fire and Rescue Service at Basingstoke fire station, which has been set up as a vaccination centre and where crews are still answering 999 calls on February 4, 2021 in Basingstoke, England.

WPA Pool | Getty Images

LONDON — The European Medicines Agency has ruled that the AstraZeneca coronavirus vaccine is safe, despite some concerns over possible side effects.

The announcement Thursday comes after more than a dozen EU nations decided to halt the use of the AstraZeneca shot, which was developed with the University of Oxford, after reports of blood clots. A few other countries have stopped using individual batches of the vaccine.

The EMA said Thursday that the benefits of the vaccine outweighed the risks. It found no batch issues or quality issues with the vaccine, although it was unable to definitively rule out a link with the blood clot incidents.

The suspensions were not uniform across the 27 member states of the European Union, however, with a number of nations continuing to deploy the AstraZeneca shot in their vaccination campaigns.

Austria was the first country to suspend the use of a specific batch of AstraZeneca shots last week, following the death of a 49-year-old woman who had received the vaccine.

This was followed by reports of blood clots elsewhere, although in a very small number of individuals, which led other heads to state to pause its use and wait for a new assessment from the region’s health authority.

AstraZeneca’s vaccine is being widely used in the U.K., but has not yet been approved by authorities in the United States.

The benefits ‘outweigh its risks’

The World Health Organization said Wednesday that “vaccination against Covid-19 will not reduce illness or deaths from other causes. Thromboembolic events are known to occur frequently.”

In addition, the WHO said that the reaction of some EU nations showed that “the surveillance system works and that effective controls are in place.” Nonetheless, the institution reiterated that it believes “the benefits of the AstraZeneca vaccine outweigh its risks and recommends that vaccinations continue.”

The U.K.’s medicines regulator also said on Thursday that people should continue to receive the AstraZeneca shot.

Some health experts have raised wider concerns over pausing the use of this vaccine. Speaking earlier this week, EMA Executive Director Emer Cooke said the institution was worried that the suspensions could affect peoples’ trust of vaccines.

The recent concerns over side affects follow uncertainty from some EU nations over a supposed lack of data on the efficacy of the AstraZeneca vaccine for elderly populations. These countries subsequently decided to go ahead with using the shot for inoculations, however.

Situation in Europe ‘getting worse’

The distribution of vaccines is crucial from both a health and economic perspective in Europe.

Speaking on Wednesday, European Commission President Ursula von der Leyen said: “The epidemiological situation is getting worse.”

“We see the crest of a third wave forming in member states, and we know that we need to accelerate the vaccination rates,” she added.

The EU is aiming to inoculate 70% of its adult population by the end of the summer.

Data presented on Wednesday suggested the bloc is on track to achieve that target, assuming that pharmaceutical firms respect their delivery contracts in the next three months and that member states are successful in using them.



READ SOURCE

This website uses cookies. By continuing to use this site, you accept our use of cookies.